Results 71 to 80 of about 26,703 (203)
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan +5 more
wiley +1 more source
Frequency of cognitive impairment in patients with neuromyelitis optica spectrum disorder in Mexico
Multiple Sclerosis Journal - Experimental, Translational and ClinicalBackground Between 29% and 67% of neuromyelitis optica spectrum disorder patients have cognitive alterations. Objective To assess the frequency of cognitive impairment in patients with neuromyelitis optica spectrum disorder in Mexico using the Brief ...
Edgar R Valdivia-Tangarife +7 more
doaj +1 more source
Neural Regeneration Research, 2019 Variants at the GTF2I repeat domain containing 1 (GTF2IRD1)–GTF2I locus are associated with primary Sjögren’s syndrome, systemic lupus erythematosus, and rheumatoid arthritis.
Jing-Lu Xie +9 more
doaj +1 more source
Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin +11 more
wiley +1 more source
Effects of physical therapy intervention in the management of neuromyelitis optica: a case report
Bulletin of Faculty of Physical Therapy, 2023 Background Neuromyelitis optica is a rare immune-mediated demyelinating central nervous system disorder affecting the spinal cord and optic nerves. There is no permanent cure for this disease, and its management requires a multidisciplinary approach ...
Sneha Chakraverty +2 more
doaj +1 more source
Immunopathological Effects Of Aquaporin-4 Ig G In Neuromyelitis Optica Spectrum Disorders [PDF]
, 2017 published_or_final_versio
Chan, KH, Ng, CL, Yick, LW
core +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Chimeric antigen receptor (CAR) T‐cell therapy has been investigated in neurological diseases, encompassing both central nervous system malignancies and autoimmune disorders, thereby extending its application beyond hematological cancers.
Omar Alqaisi +5 more
wiley +1 more source
Tonic spasms are a common clinical manifestation in patients with neuromyelitis optica
Arquivos de Neuro-Psiquiatria, 2013 Tonic spasms have been most commonly associated with multiple sclerosis. To date, few reports of series of patients with neuromyelitis optica and tonic spasms have been published.
Luz Abaroa +5 more
doaj +1 more source
SAGE Open Medical Case Reports, 2023 Neuromyelitis optica, an autoimmune inflammatory disorder affecting the central nervous system, can occur in a paraneoplastic context, although rare.
Bahadar S Srichawla +4 more
doaj +1 more source
Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4. [PDF]
, 2017 While it is recognized that aquaporin-4 (AQP4)-specific T cells and antibodies participate in the pathogenesis of neuromyelitis optica (NMO), a human central nervous system (CNS) autoimmune demyelinating disease, creation of an AQP4-targeted model with ...
Cruz-Herranz, Andrés +7 more
core +1 more source